{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:41:52Z","timestamp":1794634912837,"version":"4.9.1"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"5","funder":[{"DOI":"10.13039\/100000002","name":"NIH NCI","doi-asserted-by":"publisher","award":["SPORE-P50CA100707"],"award-info":[{"award-number":["SPORE-P50CA100707"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH NCI","doi-asserted-by":"publisher","award":["R01-CA050947"],"award-info":[{"award-number":["R01-CA050947"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH NCI","doi-asserted-by":"publisher","award":["R01CA207237"],"award-info":[{"award-number":["R01CA207237"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH NCI","doi-asserted-by":"publisher","award":["P01CA155258"],"award-info":[{"award-number":["P01CA155258"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH NCI","doi-asserted-by":"publisher","award":["R01-CA178264"],"award-info":[{"award-number":["R01-CA178264"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017544","name":"VA Healthcare System","doi-asserted-by":"publisher","award":["5I01BX001584"],"award-info":[{"award-number":["5I01BX001584"]}],"id":[{"id":"10.13039\/100017544","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>The proteasome inhibitor bortezomib induces apoptosis in multiple myeloma cells and has transformed patient outcome. Using in vitro as well as in vivo immunodeficient and immunocompetent murine multiple myeloma models, we here show that bortezomib also triggers immunogenic cell death (ICD), characterized by exposure of calreticulin on dying multiple myeloma cells, phagocytosis of tumor cells by dendritic cells, and induction of multiple myeloma\u2013specific immunity. We identify a bortezomib-triggered specific ICD gene signature associated with better outcome in two independent cohorts of patients with multiple myeloma. Importantly, bortezomib stimulates multiple myeloma cell immunogenicity via activation of the cGAS\/STING pathway and production of type I IFNs, and STING agonists significantly potentiate bortezomib-induced ICD. Our study therefore delineates mechanisms whereby bortezomib exerts immunotherapeutic activity and provides the framework for clinical trials of STING agonists with bortezomib to induce potent tumor-specific immunity and improve patient outcome in multiple myeloma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Our study demonstrates that cGAS\/STING-dependent immunostimulatory activity mediates bortezomib anti-myeloma activity in experimental models and associates with clinical response to bortezomib in patients with multiple myeloma. These findings provide the rationale for clinical evaluation of STING agonists to further potentiate anti\u2013multiple myeloma immune response.<\/jats:p>\n                    <jats:p>See related commentary by Zitvogel and Kroemer, p. 405.<\/jats:p>\n                    <jats:p>This article is highlighted in the In This Issue feature, p. 403<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-21-0047","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T10:10:20Z","timestamp":1619172620000},"page":"468-483","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":142,"title":["Bortezomib Induces Anti\u2013Multiple Myeloma Immune Response Mediated by cGAS\/STING Pathway Activation"],"prefix":"10.1158","volume":"2","author":[{"given":"Annamaria","family":"Gulla","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8850-0442","authenticated-orcid":false,"given":"Eugenio","family":"Morelli","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet K.","family":"Samur","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts."},{"name":"2Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"3Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1522-4504","authenticated-orcid":false,"given":"Cirino","family":"Botta","sequence":"additional","affiliation":[{"name":"4Department of Oncohematology, \u201cAnnunziata\u201d Hospital, Cosenza, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teru","family":"Hideshima","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3673-0104","authenticated-orcid":false,"given":"Giada","family":"Bianchi","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Fulciniti","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Malvestiti","sequence":"additional","affiliation":[{"name":"6Department of Pediatric Hematology and Oncology, Freiburg University Hospital, Freiburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rao H.","family":"Prabhala","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts."},{"name":"7VA Boston Healthcare System, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Talluri","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts."},{"name":"7VA Boston Healthcare System, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Wen","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6199-3569","authenticated-orcid":false,"given":"Yu-Tzu","family":"Tai","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharminder","family":"Chauhan","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4603-8517","authenticated-orcid":false,"given":"Tomasz","family":"Sewastianik","sequence":"additional","affiliation":[{"name":"8Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts."},{"name":"9Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben D.","family":"Carrasco","sequence":"additional","affiliation":[{"name":"8Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts."},{"name":"10Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts."},{"name":"7VA Boston Healthcare System, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"key":"2022090100012696600_bib1","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3324\/haematol.2020.247015","article-title":"Multiple myeloma: the (r)evolution of current therapy and a glance into future","volume":"105","author":"Gulla","year":"2020","journal-title":"Haematologica"},{"key":"2022090100012696600_bib2","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2022090100012696600_bib3","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood.2020006540","article-title":"Cancer immunoediting and immune dysregulation in multiple myeloma","volume":"136","author":"Nakamura","year":"2020","journal-title":"Blood"},{"key":"2022090100012696600_bib4","doi-asserted-by":"crossref","first-page":"101143","DOI":"10.1016\/j.beha.2020.101143","article-title":"Monoclonal antibodies in multiple myeloma: current and emerging targets and mechanisms of action","volume":"33","author":"Wudhikarn","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"key":"2022090100012696600_bib5","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"key":"2022090100012696600_bib6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"2022090100012696600_bib7","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J Exp Med"},{"key":"2022090100012696600_bib8","doi-asserted-by":"crossref","first-page":"e000337","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Galluzzi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2022090100012696600_bib9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/imr.12582","article-title":"Immunogenic stress and death of cancer cells: contribution of antigenicity vs adjuvanticity to immunosurveillance","volume":"280","author":"Bloy","year":"2017","journal-title":"Immunol Rev"},{"key":"2022090100012696600_bib10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat Med"},{"key":"2022090100012696600_bib11","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1172\/JCI35180","article-title":"The anticancer immune response: indispensable for therapeutic success?","volume":"118","author":"Zitvogel","year":"2008","journal-title":"J Clin Invest"},{"key":"2022090100012696600_bib12","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2022090100012696600_bib13","doi-asserted-by":"crossref","first-page":"e1637188","DOI":"10.1080\/2162402X.2019.1637188","article-title":"Clinical evidence that immunogenic cell death sensitizes to PD-1\/PD-L1 blockade","volume":"8","author":"Kepp","year":"2019","journal-title":"Oncoimmunology"},{"key":"2022090100012696600_bib14","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"2022090100012696600_bib15","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"2022090100012696600_bib16","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1182\/blood-2008-08-172734","article-title":"The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition","volume":"113","author":"Bianchi","year":"2009","journal-title":"Blood"},{"key":"2022090100012696600_bib17","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","article-title":"The proteasome and proteasome inhibitors in multiple myeloma","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"2022090100012696600_bib18","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.1182\/blood-2011-06-363911","article-title":"Bortezomib-induced \u201cBRCAness\u201d sensitizes multiple myeloma cells to PARP inhibitors","volume":"118","author":"Neri","year":"2011","journal-title":"Blood"},{"key":"2022090100012696600_bib19","doi-asserted-by":"crossref","first-page":"172458","DOI":"10.1155\/2015\/172458","article-title":"Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: impact on myeloma-induced alterations of bone remodeling","volume":"2015","author":"Accardi","year":"2015","journal-title":"Biomed Res Int"},{"key":"2022090100012696600_bib20","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2006-10-054221","article-title":"Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications","volume":"109","author":"Spisek","year":"2007","journal-title":"Blood"},{"key":"2022090100012696600_bib21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fcell.2019.00050","article-title":"Immunogenic cell death and immunotherapy of multiple myeloma","volume":"7","author":"Serrano-Del Valle","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"2022090100012696600_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2016.08.019","article-title":"Inhibition of autophagy with chloroquine potentiates carfilzomib-induced apoptosis in myeloma cells in vitro and in vivo","volume":"382","author":"Jarauta","year":"2016","journal-title":"Cancer Lett"},{"key":"2022090100012696600_bib23","doi-asserted-by":"crossref","first-page":"e1484981","DOI":"10.1080\/2162402X.2018.1484981","article-title":"Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects","volume":"7","author":"De Beck","year":"2018","journal-title":"Oncoimmunology"},{"key":"2022090100012696600_bib24","doi-asserted-by":"crossref","first-page":"15030","DOI":"10.1038\/s41598-018-33396-w","article-title":"The genetic landscape of 5T models for multiple myeloma","volume":"8","author":"Maes","year":"2018","journal-title":"Sci Rep"},{"key":"2022090100012696600_bib25","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"2022090100012696600_bib26","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1182\/blood-2006-09-044974","article-title":"Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib","volume":"109","author":"Mulligan","year":"2007","journal-title":"Blood"},{"key":"2022090100012696600_bib27","doi-asserted-by":"crossref","first-page":"D1040","DOI":"10.1093\/nar\/gks1215","article-title":"Interferome v2.0: an updated database of annotated interferon-regulated genes","volume":"41","author":"Rusinova","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"2022090100012696600_bib28","first-page":"e988042","article-title":"Autocrine signaling of type 1 interferons in successful anticancer chemotherapy","volume":"4","author":"Vacchelli","year":"2015","journal-title":"Oncoimmunology"},{"key":"2022090100012696600_bib29","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm.3708","article-title":"Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy","volume":"20","author":"Sistigu","year":"2014","journal-title":"Nat Med"},{"key":"2022090100012696600_bib30","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nri3845","article-title":"Type I interferons in anticancer immunity","volume":"15","author":"Zitvogel","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"2022090100012696600_bib31","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature14493","article-title":"Chromothripsis from DNA damage in micronuclei","volume":"522","author":"Zhang","year":"2015","journal-title":"Nature"},{"key":"2022090100012696600_bib32","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature23449","article-title":"cGAS surveillance of micronuclei links genome instability to innate immunity","volume":"548","author":"Mackenzie","year":"2017","journal-title":"Nature"},{"key":"2022090100012696600_bib33","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.immuni.2017.09.020","article-title":"cGAS Micro-manages genotoxic stress","volume":"47","author":"Motwani","year":"2017","journal-title":"Immunity"},{"key":"2022090100012696600_bib34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.molcel.2020.07.026","article-title":"DNA damage and cancer immunotherapy: a STING in the tale","volume":"80","author":"Reislander","year":"2020","journal-title":"Mol Cell"},{"key":"2022090100012696600_bib35","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41580-020-0244-x","article-title":"Molecular mechanisms and cellular functions of cGAS-STING signalling","volume":"21","author":"Hopfner","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2022090100012696600_bib36","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/imr.12765","article-title":"STING pathway agonism as a cancer therapeutic","volume":"290","author":"Flood","year":"2019","journal-title":"Immunol Rev"},{"key":"2022090100012696600_bib37","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1172\/JCI86892","article-title":"The host STING pathway at the interface of cancer and immunity","volume":"126","author":"Corrales","year":"2016","journal-title":"J Clin Invest"},{"key":"2022090100012696600_bib38","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.celrep.2019.09.089","article-title":"Magnitude of therapeutic STING activation determines CD8(+) T cell-mediated anti-tumor immunity","volume":"29","author":"Sivick","year":"2019","journal-title":"Cell Rep"},{"key":"2022090100012696600_bib39","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","article-title":"Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity","volume":"11","author":"Corrales","year":"2015","journal-title":"Cell Rep"},{"key":"2022090100012696600_bib40","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1200\/JCO.2010.28.3945","article-title":"Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)","volume":"28","author":"Avet-Loiseau","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022090100012696600_bib41","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/nm.4229","article-title":"IAP antagonists induce anti-tumor immunity in multiple myeloma","volume":"22","author":"Chesi","year":"2016","journal-title":"Nat Med"},{"key":"2022090100012696600_bib42","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40164-017-0081-6","article-title":"Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era","volume":"6","author":"Zhang","year":"2017","journal-title":"Exp Hematol Oncol"},{"key":"2022090100012696600_bib43","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"2022090100012696600_bib44","doi-asserted-by":"crossref","first-page":"e1278332","DOI":"10.1080\/2162402X.2016.1278332","article-title":"Calreticulin promotes immunity and type I interferon-dependent survival in mice with acute myeloid leukemia","volume":"6","author":"Chen","year":"2017","journal-title":"Oncoimmunology"},{"key":"2022090100012696600_bib45","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood.2019004537","article-title":"Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma","volume":"136","author":"Perez","year":"2020","journal-title":"Blood"},{"key":"2022090100012696600_bib46","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/leu.2017.334","article-title":"Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma","volume":"32","author":"Gulla","year":"2018","journal-title":"Leukemia"},{"key":"2022090100012696600_bib47","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12859-018-2139-9","article-title":"VIPER: Visualization Pipeline for RNA-seq, a Snakemake workflow for efficient and complete RNA-seq analysis","volume":"19","author":"Cornwell","year":"2018","journal-title":"BMC Bioinformatics"},{"key":"2022090100012696600_bib48","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/bioinformatics\/btp101","article-title":"ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks","volume":"25","author":"Bindea","year":"2009","journal-title":"Bioinformatics"},{"key":"2022090100012696600_bib49","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/bioinformatics\/btt019","article-title":"CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data","volume":"29","author":"Bindea","year":"2013","journal-title":"Bioinformatics"},{"key":"2022090100012696600_bib50","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1038\/s41375-018-0116-y","article-title":"Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma","volume":"32","author":"Samur","year":"2018","journal-title":"Leukemia"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/2\/5\/468\/3098972\/468.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/2\/5\/468\/3098972\/468.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T20:02:23Z","timestamp":1661976143000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/2\/5\/468\/665837\/Bortezomib-Induces-Anti-Multiple-Myeloma-Immune"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,23]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,4,23]]},"published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-21-0047","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.22543534.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22543531.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.c.6550306.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22543534","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22543531","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.c.6550306","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,23]]}}}